RA reports travel support from Amgen, Sanofi, BeOne and Pfizer and served as a consultant for Stemline and Pfizer. KA declares no competing interests. MA-B reports travel support from Stemline. LL reports travel support from Sanofi, Oncopeptides, J&J and Amgen, served as a consultant for GSK, Sanofi, J&J and Pfizer, received honoraria from Adaptive, Amgen, AbbVie, J&J, Pfizer, Sanofi, Regeneron, Takeda and AstraZeneca and received research funding from AbbVie, GSK (both to the institution) and Amgen. CB received honoraria from AOK Germany, AstraZeneca, Bayer, Berlin Chemie, Bristol Myers Squibb, GSO Research Organisation, J&J, med update, Merck Serono, MSD, Novartis, Roche and Sanofi. WA has received travel grants from J&J, Immatics and BioNTech, honoraria from GSK, Astellas, Janssen and AstraZeneca and research funding (to the institution) from Affimed and BioNTech. KW served as a consultant for AbbVie, Adaptive Biotech, Amgen, BeOne, GSK, J&J, Karyopharm, Stemline, Oncopeptides, Pfizer, Regeneron, Roche, Sanofi, and Takeda and received honoraria from AbbVie, Amgen, AstraZeneca, BeOne, Bristol Myers Squibb, Celgene, GSK, J&J, Novartis, Oncopeptides, Sanofi, Stemline, and Takeda and served on the Board of Directors or advisory committees for AbbVie, Adaptive Biotech, Amgen, BeOne, Bristol Myers Squibb, Celgene, GSK, J&J, Karyopharm, Stemline, Novartis, Oncopeptides, Pfizer, Regeneron, Roche, Sanofi, and Takeda and received research funding from AbbVie, Amgen, GSK, J&J, Pfizer, Bristol Myers Squibb, Novartis, Sanofi, and Takeda.